Citius Pharmaceuticals Inc.
| NASDAQ: CTXR | Healthcare / Biotechnology / USA |
| 0.6517 | -0.0155 | -2.32% | Vol 284.86K | 1Y Perf -47.88% |
| Oct 3rd, 2023 15:21 DELAYED |
| BID | 0.6515 | ASK | 0.6539 | ||
| Open | 0.6613 | Previous Close | 0.6672 | ||
| Pre-Market | 0.66 | After-Market | - | ||
| -0.01 -1.05% | - - |
| Target Price | 8.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 1.12K | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 2.01 | Earnings Rating | Buy | |
| Market Cap | 103.53M | Earnings Date | 10th Aug 2023 | |
| Alpha | 0.02 | Standard Deviation | 0.30 | |
| Beta | 1.40 |
Today's Price Range 0.64510.6693 | 52W Range 0.63001.71 | 5 Year PE Ratio Range -3.10-2.10 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 2.49% | ||
| 1 Month | -28.34% | ||
| 3 Months | -46.62% | ||
| 6 Months | -50.21% | ||
| 1 Year | -47.88% | ||
| 3 Years | -33.28% | ||
| 5 Years | -64.70% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -29.03 | |||
ROE last 12 Months | -31.32 | |||
ROA (5Y Avg) | -8.19 | |||
ROA last 12 Months | -28.67 | |||
ROC (5Y Avg) | -39.33 | |||
ROC last 12 Months | -24.82 | |||
Return on invested Capital Q | -7.60 | |||
Return on invested Capital Y | -28.57 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -4.00 | ||||
| 1.25 | ||||
| - | ||||
| - | ||||
| -5.40 | ||||
| -0.19 | ||||
| 3.77 | ||||
| 0.70 | ||||
| 87.30M | ||||
| Forward PE | 1.62 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 9.20 | ||||
| 9.80 | ||||
| 0.00 | ||||
| 0.01 | ||||
| -9 402.60 | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2023 | -0.06 | -0.06 | 0.00 |
| Q02 2023 | -0.04 | -0.07 | -75.00 |
| Q01 2023 | - | -0.04 | - |
| Q04 2022 | -0.04 | -0.05 | -25.00 |
| Q03 2022 | -0.05 | -0.06 | -20.00 |
| Q02 2022 | -0.08 | -0.05 | 37.50 |
| Q01 2022 | -0.06 | -0.06 | 0.00 |
| Q04 2021 | -0.03 | -0.03 | 0.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -0.04 | 0.00 | - |
| 9/2023 QR | -0.04 | 0.00 | - |
| 9/2023 FY | -0.20 | 0.00 | - |
| 9/2024 FY | 0.42 | 5.00 | Positive |
| Next Report Date | - |
| Estimated EPS Next Report | -0.05 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 284.86K |
| Shares Outstanding | 158.86K |
| Shares Float | 134.08M |
| Trades Count | 1.07K |
| Dollar Volume | 186.01K |
| Avg. Volume | 805.42K |
| Avg. Weekly Volume | 472.47K |
| Avg. Monthly Volume | 852.69K |
| Avg. Quarterly Volume | 1.09M |
Citius Pharmaceuticals Inc. (NASDAQ: CTXR) stock closed at 0.6672 per share at the end of the most recent trading day (a -2.51% change compared to the prior day closing price) with a volume of 309.74K shares and market capitalization of 103.53M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 10 people. Citius Pharmaceuticals Inc. CEO is Myron Z. Holubiak.
The one-year performance of Citius Pharmaceuticals Inc. stock is -47.88%, while year-to-date (YTD) performance is -15.54%. CTXR stock has a five-year performance of -64.7%. Its 52-week range is between 0.63 and 1.71, which gives CTXR stock a 52-week price range ratio of 2.01%
Citius Pharmaceuticals Inc. currently has a PE ratio of -4.00, a price-to-book (PB) ratio of 1.25, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -28.67%, a ROC of -24.82% and a ROE of -31.32%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Citius Pharmaceuticals Inc., there were 0 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.05 for the next earnings report. Citius Pharmaceuticals Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Citius Pharmaceuticals Inc. is Strong Buy (1), with a target price of $8, which is +1 120.07% compared to the current price. The earnings rating for Citius Pharmaceuticals Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Citius Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Citius Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 28.81, ATR14 : 0.05, CCI20 : -80.64, Chaikin Money Flow : -0.54, MACD : -0.07, Money Flow Index : 37.64, ROC : -12.19, RSI : 30.90, STOCH (14,3) : 22.45, STOCH RSI : 0.70, UO : 39.93, Williams %R : -77.55), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Citius Pharmaceuticals Inc. in the last 12-months were:
Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the development and commercialization of anti-infective products, adjunctive cancer care, and unique prescription products. Citius is currently advancing two proprietary product candidates, Mino-Lok product and a Hydrocortisone-Lidocaine formulation. Mino-Lok product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections. The company's Hydrocortisone-Lidocaine provides anti-inflammatory and anesthetic relief to patients suffering from Grade I and II hemorrhoids. It is primarily operating within the critical care and cancer care market segments.
CEO: Myron Z. Holubiak
Telephone: +1 908 967-6677
Address: 11 Commerce Drive, Cranford 07016, NJ, US
Number of employees: 10
